291 related articles for article (PubMed ID: 30286779)
1. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A
J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779
[TBL] [Abstract][Full Text] [Related]
2. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
3. Chloroquine suppresses proliferation and invasion and induces apoptosis of osteosarcoma cells associated with inhibition of phosphorylation of STAT3.
Chen C; Zhang H; Yu Y; Huang Q; Wang W; Niu J; Lou J; Ren T; Huang Y; Guo W
Aging (Albany NY); 2021 Jun; 13(13):17901-17913. PubMed ID: 34170850
[TBL] [Abstract][Full Text] [Related]
4. 4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells in vitro and in vivo xenograft model through down-regulation of the JAK2/STAT3 pathway.
Park KR; Yun HM; Quang TH; Oh H; Lee DS; Auh QS; Kim EC
Oncotarget; 2016 Feb; 7(6):6960-71. PubMed ID: 26755649
[TBL] [Abstract][Full Text] [Related]
5. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
6. Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma.
Ji XL; He M
Aging (Albany NY); 2019 Aug; 11(15):5848-5863. PubMed ID: 31422383
[TBL] [Abstract][Full Text] [Related]
7. Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo.
Mao M; Zhang T; Wang Z; Wang H; Xu J; Yin F; Wang G; Sun M; Wang Z; Hua Y; Cai Z
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1214-1225. PubMed ID: 30659925
[TBL] [Abstract][Full Text] [Related]
8. Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3.
Zhang T; Li J; Yin F; Lin B; Wang Z; Xu J; Wang H; Zuo D; Wang G; Hua Y; Cai Z
Oncogene; 2017 Nov; 36(47):6627-6639. PubMed ID: 28783167
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
10. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
11. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
13. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J
Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507
[TBL] [Abstract][Full Text] [Related]
14. Impact of STAT3 inhibition on survival of osteosarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Anticancer Res; 2014 Nov; 34(11):6537-45. PubMed ID: 25368256
[TBL] [Abstract][Full Text] [Related]
15. Catalpol suppresses osteosarcoma cell proliferation through blocking epithelial-mesenchymal transition (EMT) and inducing apoptosis.
Wang L; Xue GB
Biochem Biophys Res Commun; 2018 Jan; 495(1):27-34. PubMed ID: 29032182
[TBL] [Abstract][Full Text] [Related]
16. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma.
Tu B; Du L; Fan QM; Tang Z; Tang TT
Cancer Lett; 2012 Dec; 325(1):80-8. PubMed ID: 22743617
[TBL] [Abstract][Full Text] [Related]
17. Cinobufagin Suppresses The Characteristics Of Osteosarcoma Cancer Cells By Inhibiting The IL-6-OPN-STAT3 Pathway.
Zhang C; Ma K; Li WY
Drug Des Devel Ther; 2019; 13():4075-4090. PubMed ID: 31824138
[TBL] [Abstract][Full Text] [Related]
18. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.
Wang S; Wang Y; Huang Z; Wei H; Wang X; Shen R; Lan W; Zhong G; Lin J
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1670-1680. PubMed ID: 34693451
[TBL] [Abstract][Full Text] [Related]
19. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Duo J; Ma Y; Wang G; Han X; Zhang C
DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of Raddeanin A is mediated by Jun amino-terminal kinase activation and signal transducer and activator of transcription 3 inhibition in human osteosarcoma.
Wang Z; Shen J; Sun W; Zhang T; Zuo D; Wang H; Wang G; Xu J; Yin F; Mao M; Zhou Z; Hua Y; Cai Z
Cancer Sci; 2019 May; 110(5):1746-1759. PubMed ID: 30907478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]